Related Experiment Videos
Refraction of 1-year-old children after cycloplegia with 1% cyclopentolate: comparison with findings after
Insights
Cyclopentolate 1% offers weaker cycloplegia than atropine 1% in infants. Using atropine for pediatric eye exams could harm visual development, necessitating cyclopentolate despite its limitations.
Area of Science:
- Ophthalmology
- Pediatric Optometry
- Pharmacology
Background:
- Accurate refractive error assessment in young children is crucial for early detection of visual impairments.
- Cycloplegic agents are essential for achieving accurate refraction by paralyzing accommodation.
- The choice of cycloplegic agent can impact both the efficacy of refraction and potential side effects.
Purpose of the Study:
- To compare the efficacy of cyclopentolate 1% versus atropine 1% in inducing cycloplegia in 1-year-old children.
- To evaluate the implications of different cycloplegic agents on visual development during sensitive periods.
Main Methods:
- A comparative study involving 1-year-old children requiring cycloplegic refraction.
- Administration of cyclopentolate 1% and atropine 1% to assess the degree and duration of cycloplegia.
Main Results:
- Cyclopentolate 1% demonstrated significantly less effectiveness in producing cycloplegia compared to atropine 1% in the studied age group.
- Atropine 1% induced a more prolonged and profound cycloplegia.
Conclusions:
- Cyclopentolate 1% is less effective for cycloplegic refraction in 1-year-olds.
- The profound cycloplegia from atropine 1% may pose risks to visual development in sensitive periods.
- Clinical practice should consider the inadequacy of cyclopentolate 1% and adjust accordingly for pediatric eye examinations.
Abstract:
Cyclopentolate 1% is significantly less effective than atropine 1% at producing cycloplegia in 1-year-old children. If cycloplegic refraction is to be used for investigation or screening children for visual defects during the sensitive period, the more prolonged and profound cycloplegia following atropine could potentially have a disastrous effect on the development of vision. Cyclopentolate 1% would have to be used, and allowance made for its inadequacy as a cycloplegic.